Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Luigia Fazia

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Current Atherosclerosis Reports|April 28, 2006
Cyclooxygenase-2 inhibition: vascular inflammation and cardiovascular riskFrancesco Cipollone, Maria Luigia Fazia
Journal of Cardiovascular Pharmacology|June 21, 2006
COX-2 and atherosclerosisFrancesco Cipollone, Maria Luigia Fazia
Expert Opinion on Pharmacotherapy|February 2, 2006
Role of angiotensin II receptor blockers in atherosclerotic plaque stabilityFrancesco Cipollone, Maria Luigia Fazia, Andrea Mezzetti
Pharmacology & Therapeutics|June 24, 2008
WITHDRAWN: Cyclooxygenase and prostaglandin synthases in atherosclerosis: Recent insights and future perspectivesMaria Luigia Fazia, Andrea Mezzetti, Francesco Cipollone
Arteriosclerosis, Thrombosis, and Vascular Biology|June 4, 2005
Association between 5-lipoxygenase expression and plaque instability in humansFrancesco Cipollone, Andrea Mezzetti, Maria Luigia Fazia, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 16, 2005
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in humanFrancesco Cipollone, Maria Luigia Fazia, Annalisa Iezzi, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 14, 2006
Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetesChiara Cuccurullo, Annalisa Iezzi, Maria Luigia Fazia, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Current Atherosclerosis Reports|April 28, 2006
Cyclooxygenase-2 inhibition: vascular inflammation and cardiovascular riskFrancesco Cipollone, Maria Luigia Fazia
Journal of Cardiovascular Pharmacology|June 21, 2006
COX-2 and atherosclerosisFrancesco Cipollone, Maria Luigia Fazia
Expert Opinion on Pharmacotherapy|February 2, 2006
Role of angiotensin II receptor blockers in atherosclerotic plaque stabilityFrancesco Cipollone, Maria Luigia Fazia, Andrea Mezzetti
Pharmacology & Therapeutics|June 24, 2008
WITHDRAWN: Cyclooxygenase and prostaglandin synthases in atherosclerosis: Recent insights and future perspectivesMaria Luigia Fazia, Andrea Mezzetti, Francesco Cipollone
Arteriosclerosis, Thrombosis, and Vascular Biology|June 4, 2005
Association between 5-lipoxygenase expression and plaque instability in humansFrancesco Cipollone, Andrea Mezzetti, Maria Luigia Fazia, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|July 16, 2005
Association between prostaglandin E receptor subtype EP4 overexpression and unstable phenotype in atherosclerotic plaques in humanFrancesco Cipollone, Maria Luigia Fazia, Annalisa Iezzi, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 14, 2006
Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetesChiara Cuccurullo, Annalisa Iezzi, Maria Luigia Fazia, et al.
Pageof 1